Literature DB >> 16899402

What's new in antibiotic resistance? Focus on beta-lactamases.

Maja Babic1, Andrea M Hujer, Robert A Bonomo.   

Abstract

In gram-negative bacteria, beta-lactamases are the most important mechanism of resistance to beta-lactam antibiotics. Currently, the beta-lactamases receiving the most attention are the extended-spectrum beta-lactamases (ESBLs), inhibitor-resistant beta-lactamases and carbapenemases. When found in Escherichia coli and Klebsiella spp., ESBLs confer resistance to extended-spectrum cephalosporins, such as ceftazidime, cefotaxime and cefepime. Hence, ESBLs limit the choice of beta-lactam therapy to carbapenems. A worrisome trend is the increasing number of pathogens found in isolates from patients in the community that possess ESBLs. It is equally distressing that carbapenemases (serine and metallo-beta-lactamases) are being found in many of the same bacteria that harbor ESBLs, for example Klebsiella pneumoniae. Despite many years studying beta-lactamases, important clinical and scientific questions still remain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16899402     DOI: 10.1016/j.drup.2006.05.005

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  49 in total

1.  Conserved water molecules stabilize the Omega-loop in class A beta-lactamases.

Authors:  Fabian Bös; Jürgen Pleiss
Journal:  Antimicrob Agents Chemother       Date:  2008-01-14       Impact factor: 5.191

Review 2.  Resistance to antibiotics targeted to the bacterial cell wall.

Authors:  I Nikolaidis; S Favini-Stabile; A Dessen
Journal:  Protein Sci       Date:  2014-01-17       Impact factor: 6.725

3.  Influence of substrates and inhibitors on the structure of Klebsiella pneumoniae carbapenemase-2.

Authors:  Ben A Shurina; Richard C Page
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-04

Review 4.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

Review 5.  Fragment-based inhibitor discovery against β-lactamase.

Authors:  Derek A Nichols; Adam R Renslo; Yu Chen
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

6.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

Review 7.  β-Lactams and β-Lactamase Inhibitors: An Overview.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

8.  In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains.

Authors:  Naoki Kohira; Joshua West; Akinobu Ito; Tsukasa Ito-Horiyama; Rio Nakamura; Takafumi Sato; Stephen Rittenhouse; Masakatsu Tsuji; Yoshinori Yamano
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191

9.  Comparative sequence analysis of a multidrug-resistant plasmid from Aeromonas hydrophila.

Authors:  Carmelo S Del Castillo; Jun-Ichi Hikima; Ho-Bin Jang; Seong-Won Nho; Tae-Sung Jung; Janenuj Wongtavatchai; Hidehiro Kondo; Ikuo Hirono; Haruko Takeyama; Takashi Aoki
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

10.  Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates.

Authors:  Johann D D Pitout; Deirdre L Church; Daniel B Gregson; Barbara L Chow; Melissa McCracken; Michael R Mulvey; Kevin B Laupland
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.